Mark Cuban - AI Industrialization & Drug Transparency with Cost Plus Drugs | The Daily Show

Your video will begin in 10
Skip ad (5)
How to make $100 per day with your email list

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Added by admin
18 Views
Entrepreneur and minority owner of the NBA’s Dallas Mavericks, Mark Cuban, joins Jon Stewart to discuss disrupting the healthcare industry as co-founder of Cost Plus Drug Company. They discuss Silicon Valley’s goals of anointing Trump as CEO of America and serving as board members, the unpredictable future of AI, how Elon Musk utilizes X (formerly Twitter) algorithms to control the global discourse, and how drug price transparency has changed the future of our healthcare system. #DailyShow #ElonMusk #SiliconValley #AI

Subscribe to The Daily Show:
https://www.youtube.com/channel/UCwWhs_6x42TyRM4Wstoq8HA/?sub_confirmation=1

Follow The Daily Show:
Twitter: https://twitter.com/TheDailyShow
Facebook: https://www.facebook.com/thedailyshow
Instagram: https://www.instagram.com/thedailyshow

Stream full episodes of The Daily Show on Paramount+: http://www.paramountplus.com/?ftag=PPM-05-10aei0b

Follow Comedy Central:
Twitter: https://twitter.com/ComedyCentral
Facebook: https://www.facebook.com/ComedyCentral
Instagram: https://www.instagram.com/comedycentral

Watch full episodes of The Daily Show: https://www.cc.com/shows/the-daily-show

About The Daily Show:
Jon Stewart and The Best F**king News Team host The Daily Show, an Emmy and Peabody Award-winning program analyzing the biggest stories in news, politics, and culture through a sharp, satirical lens. The Daily Show redefined the late night show category on TV and, with an audience of over 51M across social media platforms, has become a launching pad for some of the biggest stars in entertainment.

The Daily Show airs weeknights at 11/10c on Comedy Central.
Category
Artificial Intelligence
Tags
the daily show, the daily show episodes, comedy central

Post your comment

Comments

Be the first to comment